Inceptor Bio doses first subject in trial of IB-T101 for renal cell carcinoma
US-based biotechnology company Inceptor Bio has dosed the first subject in the investigator-initiated trial of its lead ...
PipelineReview.com1d
Inceptor Bio Announces First Patient Dosed in Clinical Trial of IB-T101 for Clear Cell Renal Cell Carcinoma (ccRCC) and $21M Series A2 Financing
RESEARCH TRIANGLE PARK, NC, USA I5, 2025 I Inceptor Bio, a clinical-stage biotechnology company pioneering next-generation cell therapies, today ...
THE WEEK26d
Best memoirs and biographies to read in 2025
"It feels more like a coolly researched biography than one written by a passionate fan." What's more, Will Hermes tries to repackage the "violently aggressive, drug-huffing", gender-bending ...